Annual EBITDA
-$30.05 M
+$14.54 M+32.61%
31 December 2023
Summary:
NRx Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$30.05 million, with the most recent change of +$14.54 million (+32.61%) on 31 December 2023. During the last 3 years, it has risen by +$21.34 million (+41.53%). NRXPW annual EBITDA is now -6198.86% below its all-time high of $492.63 thousand, reached on 31 December 2019.NRXPW EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.66 M
+$6.25 M+79.04%
30 September 2024
Summary:
NRx Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.66 million, with the most recent change of +$6.25 million (+79.04%) on 30 September 2024. Over the past year, it has increased by +$4.39 million (+72.56%). NRXPW quarterly EBITDA is now -100.01% below its all-time high of $20.43 billion, reached on 31 December 2021.NRXPW Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$20.11 M
+$4.39 M+17.91%
30 September 2024
Summary:
NRx Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$20.11 million, with the most recent change of +$4.39 million (+17.91%) on 30 September 2024. Over the past year, it has dropped by -$14.06 million (-232.53%). NRXPW TTM EBITDA is now -100.10% below its all-time high of $20.39 billion, reached on 30 June 2022.NRXPW TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NRXPW EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +32.6% | +72.6% | -232.5% |
| 3 y3 years | +41.5% | +92.0% | +68.2% |
| 5 y5 years | - | -2314.0% | -4032.1% |
NRXPW EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +74.0% | -100.0% | +92.0% | -100.1% | +68.2% |
| 5 y | 5 years | -6198.9% | +74.0% | -100.0% | +93.5% | -100.1% | +68.2% |
| alltime | all time | -6198.9% | +74.0% | -100.0% | +93.5% | -100.1% | +68.2% |
NRx Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.66 M(-79.0%) | -$20.11 M(-17.9%) |
| June 2024 | - | -$7.91 M(+25.9%) | -$24.49 M(+47.7%) |
| Mar 2024 | - | -$6.29 M(+48.2%) | -$16.58 M(+61.1%) |
| Dec 2023 | -$30.05 M(-32.6%) | -$4.24 M(-29.8%) | -$10.29 M(+70.2%) |
| Sept 2023 | - | -$6.05 M(-36.9%) | -$6.05 M(-100.0%) |
| Dec 2022 | -$44.59 M(-61.5%) | - | - |
| June 2022 | - | -$9.58 M(-39.0%) | $20.39 B(+0.0%) |
| Mar 2022 | - | -$15.70 M(-100.1%) | $20.38 B(+0.0%) |
| Dec 2021 | -$115.79 M | $20.43 B(<-9900.0%) | $20.37 B(<-9900.0%) |
| Sept 2021 | - | -$20.77 M(+29.8%) | -$63.16 M(+32.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$16.00 M(-37.2%) | -$47.54 M(+51.2%) |
| Mar 2021 | - | -$25.48 M(+2708.4%) | -$31.43 M(+460.8%) |
| Dec 2020 | -$51.38 M(<-9900.0%) | -$907.41 K(-82.4%) | -$5.60 M(+18.8%) |
| Sept 2020 | - | -$5.15 M(-5011.4%) | -$4.72 M(-1030.3%) |
| June 2020 | - | $104.82 K(-69.7%) | $506.92 K(-18.1%) |
| Mar 2020 | - | $345.85 K(-1951.8%) | $618.80 K(+25.6%) |
| Dec 2019 | $492.63 K | -$18.68 K(-124.9%) | $492.63 K(-3.7%) |
| Sept 2019 | - | $74.93 K(-65.4%) | $511.31 K(+17.2%) |
| June 2019 | - | $216.70 K(-1.4%) | $436.38 K(+98.6%) |
| Mar 2019 | - | $219.68 K | $219.68 K |
FAQ
- What is NRx Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for NRx Pharmaceuticals?
- What is NRx Pharmaceuticals annual EBITDA year-on-year change?
- What is NRx Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for NRx Pharmaceuticals?
- What is NRx Pharmaceuticals quarterly EBITDA year-on-year change?
- What is NRx Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for NRx Pharmaceuticals?
- What is NRx Pharmaceuticals TTM EBITDA year-on-year change?
What is NRx Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of NRXPW is -$30.05 M
What is the all time high annual EBITDA for NRx Pharmaceuticals?
NRx Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $492.63 K
What is NRx Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, NRXPW annual earnings before interest, taxes, depreciation & amortization has changed by +$14.54 M (+32.61%)
What is NRx Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of NRXPW is -$1.66 M
What is the all time high quarterly EBITDA for NRx Pharmaceuticals?
NRx Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $20.43 B
What is NRx Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, NRXPW quarterly earnings before interest, taxes, depreciation & amortization has changed by +$4.39 M (+72.56%)
What is NRx Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of NRXPW is -$20.11 M
What is the all time high TTM EBITDA for NRx Pharmaceuticals?
NRx Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $20.39 B
What is NRx Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, NRXPW TTM earnings before interest, taxes, depreciation & amortization has changed by -$14.06 M (-232.53%)